Daewoong Pharmaceutical said Wednesday that it has signed an industry-university cooperation agreement with Yonsei University’s Songdam Institute for Cancer Research to develop a customized diagnosis and treatment system based on genome information.

Songdam Institute for Cancer Research Director Chung Hyun-chul (third from left) and Kim Yang-seok, head of Daewoong’s healthcare AI business, hold up a cooperation agreement at Severance Hospital in Sinchon-dong, Seoul.

Under the agreement, the two institutions will cooperate in R&D and commercialization for immunotherapy. Daewoong will provide precise medical analysis technology and development infrastructure, while Songdam Institute will develop a diagnosis and treatment system for customized chemotherapy based on genetic information.

The two sides will also continue to expand the exchange of research personnel, technology, and information.

“Songdam Institute for Cancer Research is a great partner in the development of precise medical research and development for tumors,” said Kim Yang-seok, head of Daewoong’s healthcare AI business. “Through this agreement, we hope to accelerate the development of optimal customized medical system platform.”

Songdam Institute for Cancer Research director Chung Hyun-chul also said, “By combining the clinical competencies of Daewoong Pharm and our center, we will contribute to the lives of cancer patients and their families.”

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>